GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius

GSK has li­censed a small mol­e­cule for Parkin­son’s and is team­ing up on ad­di­tion­al tar­gets for the dis­ease and an­oth­er undis­closed neu­rode­gen­er­a­tive con­di­tion with Flag­ship …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER